Hematologists, hematopathologists, cellular biologists, immunologists, and molecular biologists are invited to contribute to Hemato, an international open access journal on hematology. Clinical data regarding diagnosis and management are primarily addressed to clinical specialists, while advances in pathogenesis, molecular epidemiology, genetics, immunogenetics, and immunotherapy about neoplastic and non-neoplastic blood diseases are primarily addressed to biologists, epidemiologists, pharmacologists, and immunologists.

Editor-in-Chief
Prof. Dr. Antonino Carbone

Section Editors-in-Chief
Dr. Alberto Signore
Dr. Anna Sureda
Dr. Grigoris T. Gerotziafas
Dr. Laurent Garderet

Aims
Hemato (ISSN 2673-6357) is an open access journal of scientific research on hematology that publishes regular research papers, reviews, communications, and case reports covering all aspects of hematology, from pathogenesis to diagnosis and personalized management. Our aim is to improve the study of clinical and basic research of blood-related diseases.
Scope
- Leukemias
- Lymphomas
- Amyloidosis
- Coagulation
- Plasma cell disorders
- Neoplastic and non-neoplastic blood disorders
- Immunotherapy
- Targeted therapy
- Cell transplantation
- SPECT, PET, CT, MRI and other diagnostic tests in hematological disorders

Author Benefits

Open Access
Unlimited open access for readers

No Copyright Constraints
Retain copyright of your work and free use of your work

Thorough Peer-Review

Discounts on Article Processing Charges (APC)
If you belong to an institute that participates with the MDPI Institutional Open Access Program

No Space Constraints, No Extra Space or Color Charges
No restriction on the maximum length of the papers, number of figures or colors

Coverage by Leading Indexing Services
ESCI (Web of Science), Scopus, EBSCO, and other databases

Rapid Publication
A first decision is provided to authors approximately 28.1 days after submission; acceptance to publication is undertaken in 7.9 days (median values for papers published in this journal in the second half of 2023)
Affiliated Societies:
Spanish Society of Hematology and Hemotherapy (SEHH)
Nuclear Medicine Discovery (Nu.Me.D.)